Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Cancer Lett
    November 2026
  1. DOMENICHINI M, Corsini M, Ravelli C, Ricci A, et al
    Oncogenic VEGFR2 rewires the extracellular matrix to impair endothelial mechanics and destabilize tumor vasculature.
    Cancer Lett. 2026;661:218848.
    >> Share

  2. KUMAR D, Silvestri V, Edmondson EF, Khan I, et al
    Preclinical evaluation of trastuzumab deruxtecan in a new HER2+ leptomeningeal colonization model.
    Cancer Lett. 2026;660:218786.
    >> Share

    September 2026
  3. LI Y, Yuan B, Liu J, Wang X, et al
    PRMT1 and YBX1 Cooperatively Transcriptionally Activate GPX4 to Inhibit Ferroptosis and Promote Breast Cancer Progression.
    Cancer Lett. 2026 Sep 22:218849. doi: 10.1016/j.canlet.2026.218849.
    >> Share

  4. ADELEYE K, Seagroves TN, Li W
    Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis.
    Cancer Lett. 2026 Sep 15:218844. doi: 10.1016/j.canlet.2026.218844.
    >> Share

  5. WANG H, Zhang Y, Liu D, Liu C, et al
    A Copper(I)-Azurin complex suppresses p53-mediated glycolysis to sensitize breast cancer to cuproptosis with MRI monitoring.
    Cancer Lett. 2026;660:218831.
    >> Share

  6. JI P, Wu HL, He LH, Wang H, et al
    Integrated analysis reveals the impact of obesity on triple-negative breast cancer.
    Cancer Lett. 2026;660:218833.
    >> Share

  7. MA S, Chen M, Sun X, Wei B, et al
    Tamoxifen enhances radiation efficacy by promoting M1 polarization of tumor associated macrophages via JNK/c-JUN pathway.
    Cancer Lett. 2026;655:218609.
    >> Share

    August 2026
  8. LIAO Y, Yin S, Peng EY, Wu J, et al
    The GCN5L2-SIX1 complex drives glycolysis to promote progression of triple-negative breast cancer.
    Cancer Lett. 2026 Aug 14:218770. doi: 10.1016/j.canlet.2026.218770.
    >> Share

  9. LI Z, Sun X, Zheng J, Sun X, et al
    Stress-inducible circSCLT1 scaffolds HNRNPA1/CSDE1 to amplify IL1B/NF-kappaB signaling in TNBC via mRNA stabilization, suppressor degradation, and stress granule shielding.
    Cancer Lett. 2026;652:218561.
    >> Share

    July 2026
  10. ZHANG J, Miao N, Guo Y, Liu Y, et al
    Targeting tumor cell-intrinsic POU4F1 enhances antitumor immunity and sensitizes tumors to immunotherapy in basal-like breast cancer by modulating macrophage recruitment and polarization.
    Cancer Lett. 2026 Jul 23:218763. doi: 10.1016/j.canlet.2026.218763.
    >> Share

  11. LI J, Yang D, Lv R, Jin Y, et al
    Single-cell mapping of extrachromosomal circular DNA architecture and evolution in cutaneous squamous cell carcinoma.
    Cancer Lett. 2026;658:218735.
    >> Share

  12. YU Y, Liu L, Cai Y, Wang T, et al
    Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer.
    Cancer Lett. 2026 Jul 15:218737. doi: 10.1016/j.canlet.2026.218737.
    >> Share

  13. WANG X, Hua R, Riquelme MA, Zhang J, et al
    Mechano-activation of Osteocytic Connexin Hemichannels Prime Microenvironment in Suppressing Breast Cancer Bone Metastasis.
    Cancer Lett. 2026 Jul 9:218722. doi: 10.1016/j.canlet.2026.218722.
    >> Share

    June 2026
  14. ZHAO H, Tian H, Nuerbieke T, Ma K, et al
    Immunotherapy Resistance in Triple-Negative Breast Cancer: Mechanisms and Emerging Therapeutic Strategies.
    Cancer Lett. 2026 Jun 20:218690. doi: 10.1016/j.canlet.2026.218690.
    >> Share

  15. LIN LL, Bai JW, Song L, Lou KL, et al
    GSH-Activatable Rare-Earth Nanoprobe for NIR-II Fluorescence Imaging-Guided Surgery and Enhanced Chemotherapy/Chemodynamic Therapy of Breast Cancer.
    Cancer Lett. 2026 Jun 11:218677. doi: 10.1016/j.canlet.2026.218677.
    >> Share

    May 2026
  16. ROY A, Ghosh A, Bhoumick A, Paul S, et al
    Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression.
    Cancer Lett. 2026;655:218646.
    >> Share

  17. ZHAO Z, Zheng ZY, Lei JT, Baik MJ, et al
    NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis.
    Cancer Lett. 2026;655:218636.
    >> Share

  18. GHOSH D, White B, Lu X, Perricone M, et al
    Autophagy is essential for survival and function of polyploid giant cancer cells under therapeutic stress.
    Cancer Lett. 2026;646:218431.
    >> Share

  19. SABIT H, Ghazy A, Albogami KFKM, Abdelhadi OE, et al
    Circadian rhythms as orchestrators of breast cancer metastasis: From molecular mechanisms to chronotherapeutic interventions.
    Cancer Lett. 2026;653:218588.
    >> Share

  20. NAND PK, Croucher DR, Khachigian LM
    Challenges in Triple Negative Breast Cancer Treatment and Therapeutic Potential of the Mitogen Activated Protein Kinase Pathway.
    Cancer Lett. 2026 May 2:218556. doi: 10.1016/j.canlet.2026.218556.
    >> Share

  21. YUAN Q, Zhang H, Zhang N, Qian Y, et al
    BPHL promotes TNBC stemness by resolving R-loops via POLR2A lactylation inhibition and BARD1-mediated ubiquitination.
    Cancer Lett. 2026;645:218388.
    >> Share

    April 2026
  22. ZHANG S, Shi Z, Du S, Zhu T, et al
    Integration of longitudinal MRI and biopsy whole slide images for early prediction of neoadjuvant therapy response and personalized management in breast cancer: A multicenter retrospective and prospective study.
    Cancer Lett. 2026;650:218508.
    >> Share

  23. YING XH, Zhang KY, Jiang SH, Chen L, et al
    Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancer Patients.
    Cancer Lett. 2026 Apr 11:218503. doi: 10.1016/j.canlet.2026.218503.
    >> Share

  24. HONG L, Lee S, Frisbie L, Zhao Y, et al
    Nitroalkenes Exploit Dependence on Autophagy-Lysosome Pathway in PARPi-Resistant Triple Negative Breast Cancer.
    Cancer Lett. 2026 Apr 11:218504. doi: 10.1016/j.canlet.2026.218504.
    >> Share

  25. ARBEL R, Rokach L, Razi T, Tadmor T, et al
    Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients.
    Cancer Lett. 2026;643:218319.
    >> Share

  26. LEU JS, Deng H, Tran HN, Wei X, et al
    Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis.
    Cancer Lett. 2026;649:218491.
    >> Share

  27. SABIT H, Yadav AK, Salimy S, Sakr A, et al
    Integrating Multi-Omics and Artificial Intelligence for Personalized Breast Cancer Management: A Guide to Clinicians.
    Cancer Lett. 2026 Apr 3:218468. doi: 10.1016/j.canlet.2026.218468.
    >> Share

    March 2026
  28. WU P, Ge J, Hou X, Qu H, et al
    A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma.
    Cancer Lett. 2026;648:218459.
    >> Share

  29. GEORGES-CALDERON N, Fuentes C, Hidalgo Y, Grunenwald F, et al
    Melanoma cells release dysfunctional mitochondria to the tumor microenvironment and circulation in association with tumor progression.
    Cancer Lett. 2026;647:218457.
    >> Share

  30. WANG C, Sun J, Song J, Li S, et al
    Functional nanoplatforms overcoming immune resistance in skin cancers: Targeted immunomodulation, immunogenic cell death, and metabolic remodeling.
    Cancer Lett. 2026;647:218439.
    >> Share

  31. RUMNIEKS F, Vainshelbaum NM, Salmina K, Lazovska M, et al
    Resistance of BRAF(V600E)-mutant melanoma to Vemurafenib: a senescence-induced swing from differentiation to blastulation followed by proliferation.
    Cancer Lett. 2026 Mar 12:218430. doi: 10.1016/j.canlet.2026.218430.
    >> Share

  32. GAO YY, Lou KL, Lin LL, Li CX, et al
    A NIR-? fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer.
    Cancer Lett. 2026;646:218429.
    >> Share

  33. MOHOLKAR DN, Kandimalla R, Jeyabalan J, Singhal R, et al
    Exosomal Cannabidiol: A Promising Candidate for Targeted Oral Delivery against Breast Cancer.
    Cancer Lett. 2026 Mar 9:218416. doi: 10.1016/j.canlet.2026.218416.
    >> Share

  34. DAI Y, Wu X, Cheng X, Shang J, et al
    tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer.
    Cancer Lett. 2026;646:218408.
    >> Share

    February 2026
  35. GROZA P, Kumari K, Esteva-Socias M, Schott J, et al
    Fibrillarin-dependent 2'-O-methylation modulates RPS28 ribosome incorporation and oncogenic translation.
    Cancer Lett. 2026;639:218124.
    >> Share

  36. YANG C, Liu J, Kang X, Wang Z, et al
    PANX1-mediated NLRP3 inflammasome activation promotes an adaptive doxorubicin resistance through IL-1beta signaling in breast cancer.
    Cancer Lett. 2026;645:218387.
    >> Share

  37. WU CS, Chen HF, Huynh KT, Huang WC, et al
    Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy.
    Cancer Lett. 2026 Feb 24:218349. doi: 10.1016/j.canlet.2026.218349.
    >> Share

  38. XU S, Huang Z, Li Y, Lu L, et al
    Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology.
    Cancer Lett. 2026 Feb 22:218359. doi: 10.1016/j.canlet.2026.218359.
    >> Share

  39. VERMA S, Singh V, Lang JE, Gupta S, et al
    Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics.
    Cancer Lett. 2026;645:218350.
    >> Share

  40. XUE X, Ji D, Xue L, Tan Y, et al
    Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE Trial.
    Cancer Lett. 2026 Feb 18:218327. doi: 10.1016/j.canlet.2026.218327.
    >> Share

  41. FU Y, Jiang C, Chen Y, Li F, et al
    Pharmacological inhibition of histone deacetylase 6 and DNA damage repair enhances radiosensitivity in melanoma.
    Cancer Lett. 2026 Feb 17:218322. doi: 10.1016/j.canlet.2026.218322.
    >> Share

  42. ZHAO Z, Jia W, Li Z, Shi S, et al
    Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 Axis Disrupts Metabolic-Epigenetic Crosstalk and Suppresses Progression in Hyperglycolytic Breast Cancer.
    Cancer Lett. 2026 Feb 16:218328. doi: 10.1016/j.canlet.2026.218328.
    >> Share

    January 2026
  43. XIA F, Zhu X, Li X, Yi Q, et al
    FIG4 Downregulation-Arrested Autophagy-lysosomal Degradation of IL-18 Drives Lipid-Associated Macrophage Polarization and Immunotherapy Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2026 Jan 21:218278. doi: 10.1016/j.canlet.2026.218278.
    >> Share

  44. DIAO Y, Chen X, Huang Z, Tan Q, et al
    Cutting-Edge AI Technologies in Skin Cancer Applications.
    Cancer Lett. 2026 Jan 14:218256. doi: 10.1016/j.canlet.2026.218256.
    >> Share

    December 2025
  45. LI J, Li Z, Zhang X, Zhang H, et al
    Histone lactylation bridges metabolic reprogramming with chromatin-immune crosstalk in triple-negative breast cancer.
    Cancer Lett. 2025;639:218227.
    >> Share

  46. SAFAEI M, Li YC, Chen CY, Hsieh PH, et al
    Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer.
    Cancer Lett. 2025;639:218225.
    >> Share

  47. YOU Y, Wei L, Dai M, Zhao G, et al
    BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis.
    Cancer Lett. 2025;639:218175.
    >> Share

  48. VESUNA F, Winnard PT Jr, van Voss MH, Bol GM, et al
    Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.
    Cancer Lett. 2025;634:218065.
    >> Share

  49. DUAN F, Zhang C, Wu Z, Zhuang L, et al
    Copper Orchestrates Triple-negative Breast Cancer Progression via the STEAP3-dependent CDK16-JAK1 Activation.
    Cancer Lett. 2025 Dec 1:218192. doi: 10.1016/j.canlet.2025.218192.
    >> Share

    November 2025
  50. GENG D, Chen J, Sanchez A, Davalos SA, et al
    Melanoma Leverages Innate Immune IRAK-M Signaling to Limit Metastasis Through PTPN22-Induced Signaling Repression.
    Cancer Lett. 2025 Nov 27:218172. doi: 10.1016/j.canlet.2025.218172.
    >> Share

    October 2025
  51. DHRUBA SR, Sahni S, Wang B, Wu D, et al
    Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
    Cancer Lett. 2025 Oct 30:218101. doi: 10.1016/j.canlet.2025.218101.
    >> Share

  52. KRAWCZYNSKA N, Wang Y, Lim K, Das Gupta A, et al
    Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.
    Cancer Lett. 2025 Oct 28:218105. doi: 10.1016/j.canlet.2025.218105.
    >> Share

  53. YAZDI N, Pourjamal N, Katainen R, Vaananen J, et al
    Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.
    Cancer Lett. 2025;630:217900.
    >> Share

    September 2025
  54. MURR N, Richter C, Gupta SK, Hammer E, et al
    TAp73alpha drives cancer metastasis via PPI-mediated derepression of the neuronal HDAC2/REST-GABBR2 axis.
    Cancer Lett. 2025;628:217867.
    >> Share

  55. CHEN Y, Wang X, Li H, Zhang Z, et al
    Oncoprotein SND1-enriched exosomes facilitate melanoma lung metastasis by regulating CD47-SIRPalpha-mediated macrophage reprogramming.
    Cancer Lett. 2025 Sep 25:218037. doi: 10.1016/j.canlet.2025.218037.
    >> Share

  56. TAN C, Lyu H, Ruan S, Wu Y, et al
    Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis.
    Cancer Lett. 2025 Sep 2:218001. doi: 10.1016/j.canlet.2025.218001.
    >> Share

  57. LIU K, Hoover AR, Sun Y, Valerio TI, et al
    Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.
    Cancer Lett. 2025;627:217825.
    >> Share

    August 2025
  58. LI C, Gao T, Zhao Q, Li Z, et al
    Inhibition of CPT1A activates the cGAS/STING pathway to enhance neutrophil-mediated tumor abrogation in triple-negative breast cancer.
    Cancer Lett. 2025;633:217991.
    >> Share

    July 2025
  59. RUPP B, Nagpal N, Thanasiu B, Tuck K, et al
    Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.
    Cancer Lett. 2025;623:217703.
    >> Share

  60. WOHLFEIL SA, Weller C, Dietsch B, Agardy DA, et al
    Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis.
    Cancer Lett. 2025 Jul 24:217950. doi: 10.1016/j.canlet.2025.217950.
    >> Share

  61. CAI MY, Yin P, Wang ZW, Huang YZ, et al
    Dual Regulation of FZD1/7 by IGF2BP3 Enhances Stem-like Properties and Carboplatin Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2025 Jul 22:217944. doi: 10.1016/j.canlet.2025.217944.
    >> Share

  62. ZHANG M, Tang C, Li S, Jiang X, et al
    NSUN2-mediated m(5)C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis.
    Cancer Lett. 2025 Jul 19:217939. doi: 10.1016/j.canlet.2025.217939.
    >> Share

  63. WANG SC, Shen YC, Pan MR, Ou-Yang F, et al
    Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan.
    Cancer Lett. 2025 Jul 10:217912. doi: 10.1016/j.canlet.2025.217912.
    >> Share

  64. DI RUSSO S, Borsatti GE, Bouzidi A, Liberati FR, et al
    NF-kappaB-mediated cytokine secretion and glutamate metabolic reprogramming converge in breast cancer brain tropism.
    Cancer Lett. 2025 Jul 8:217907. doi: 10.1016/j.canlet.2025.217907.
    >> Share

  65. TAKAO S, Furumoto H, Furusawa A, Kano M, et al
    Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies.
    Cancer Lett. 2025 Jul 7:217906. doi: 10.1016/j.canlet.2025.217906.
    >> Share

    June 2025
  66. HAYKAL MM, Rodrigues-Ferreira S, El Botty R, Sourd L, et al
    Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.
    Cancer Lett. 2025;620:217665.
    >> Share

  67. SABIT H, Adel A, Abdelfattah MM, Ramadan RM, et al
    The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities.
    Cancer Lett. 2025;628:217865.
    >> Share

  68. WANG W, Yang H, Passang T, Li Y, et al
    Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis.
    Cancer Lett. 2025 Jun 5:217855. doi: 10.1016/j.canlet.2025.217855.
    >> Share

  69. ZHOU W, Ding Q
    Advancing Neoadjuvant Therapy with Inetetamab for HER2-Positive Breast Cancer.
    Cancer Lett. 2025 Jun 5:217852. doi: 10.1016/j.canlet.2025.217852.
    >> Share

    May 2025
  70. WU R, Yu S, Bi A, Li Y, et al
    Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
    Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823.
    >> Share

  71. ELAYAPILLAI SP, Dogra S, Hladik C, Lausen J, et al
    Preferential Release of microRNAs via Extracellular Vesicles is Associated with Ductal Carcinoma In Situ to Invasive Breast Cancer Progression.
    Cancer Lett. 2025 May 17:217794. doi: 10.1016/j.canlet.2025.217794.
    >> Share

  72. ZUO WJ, Ma LX, Wang ZH, Cao XC, et al
    Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.
    Cancer Lett. 2025 May 10:217785. doi: 10.1016/j.canlet.2025.217785.
    >> Share

  73. LIU S, Chen H, Gagea M, Federico L, et al
    ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.
    Cancer Lett. 2025 May 6:217775. doi: 10.1016/j.canlet.2025.217775.
    >> Share

  74. JIANG C, Qian Y, Bai X, Li S, et al
    SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway.
    Cancer Lett. 2025;617:217612.
    >> Share

    April 2025
  75. GRIMSLEY HE, Antczak M, Reddin IG, Weiler N, et al
    Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.
    Cancer Lett. 2025 Apr 27:217754. doi: 10.1016/j.canlet.2025.217754.
    >> Share

  76. TANG R, Xu X, Yang W, Yu W, et al
    Corrigendum to "MED27 promotes melanoma growth by targeting AKT/MAPK and NF/kappaB/iNOS signaling pathway" [Cancer Lett. 373(1) (2016) 77-87 PMID 26797421].
    Cancer Lett. 2025;623:217717.
    >> Share

  77. XIE Y, Xie J, Huang G, Zhang J, et al
    Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple negative breast cancer.
    Cancer Lett. 2025 Apr 21:217734. doi: 10.1016/j.canlet.2025.217734.
    >> Share

  78. TIAN H, Chen Y, Dong X, Fan X, et al
    The m(6)A hypermethylation-induced PIR overexpression regulates H3K4me3 and promotes Tumorigenesis of Uveal Melanoma.
    Cancer Lett. 2025 Apr 17:217729. doi: 10.1016/j.canlet.2025.217729.
    >> Share

  79. KUNDU M, Greer YE, Lobanov A, Ridnour L, et al
    TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
    Cancer Lett. 2025;620:217692.
    >> Share

    March 2025
  80. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    >> Share

  81. UEMOTO Y, Lin CA, Wang B, Ye D, et al
    Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.
    Cancer Lett. 2025;619:217668.
    >> Share

  82. HOSSAIN SM, Gimenez G, Stockwell P, Weeks R, et al
    Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy.
    Cancer Lett. 2025 Mar 13:217638. doi: 10.1016/j.canlet.2025.217638.
    >> Share

  83. WANG Z, He K, Liu M, Lv W, et al
    Enhanced mitochondrial biogenesis facilitates the development of cutaneous squamous cell carcinoma.
    Cancer Lett. 2025 Mar 10:217623. doi: 10.1016/j.canlet.2025.217623.
    >> Share

  84. YOU X, Hu X, Sun Z, Xu W, et al
    Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
    Cancer Lett. 2025;612:217493.
    >> Share

  85. GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al
    Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages.
    Cancer Lett. 2025;612:217468.
    >> Share

    February 2025
  86. MARRANCI A, Maresca L, Lodovichi S, Luserna di Rora AG, et al
    PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research.
    Cancer Lett. 2025 Feb 28:217599. doi: 10.1016/j.canlet.2025.217599.
    >> Share

  87. ZENG Z, Yi Z, Xu B
    The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients.
    Cancer Lett. 2025 Feb 19:217574. doi: 10.1016/j.canlet.2025.217574.
    >> Share

  88. CHEN H, Lin L, Qiao Z, Pei Y, et al
    YTHDF3 drives tumor growth and metastasis by recruiting eIF4B to promote Notch2 translation in breast cancer.
    Cancer Lett. 2025;614:217534.
    >> Share

  89. URZI O, Olofsson Bagge R, Crescitelli R
    Extracellular vesicles in uveal melanoma - biological roles and diagnostic value.
    Cancer Lett. 2025 Feb 4:217531. doi: 10.1016/j.canlet.2025.217531.
    >> Share

    January 2025
  90. ZHANG R, Jiang WJ, Zhao S, Kang LJ, et al
    FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer.
    Cancer Lett. 2025 Jan 17:217463. doi: 10.1016/j.canlet.2025.217463.
    >> Share

  91. TAN N, Xia C, Yan X, Cao M, et al
    Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.
    Cancer Lett. 2025 Jan 13:217457. doi: 10.1016/j.canlet.2025.217457.
    >> Share

  92. USAMA M, Hsu YC, Safaei M, Chen CY, et al
    Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells.
    Cancer Lett. 2025;611:217453.
    >> Share

    December 2024
  93. JIA Y, Chen Y, Chen M, He M, et al
    Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis.
    Cancer Lett. 2024 Dec 28:217423. doi: 10.1016/j.canlet.2024.217423.
    >> Share

  94. WANG K, He Q, Jiang X, Wang T, et al
    Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG.
    Cancer Lett. 2024 Dec 21:217409. doi: 10.1016/j.canlet.2024.217409.
    >> Share

  95. VAN TRIMPONT M, Schalk AM, Hofkens K, Peeters E, et al
    A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low) leukemia and solid cancer mouse xenograft models.
    Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404.
    >> Share

    November 2024
  96. MUGHAL MJ, Zhang Y, Li Z, Zhou S, et al
    TFAP2C-DDR1 Axis Regulates Resistance to CDK4/6 Inhibitor in Breast Cancer.
    Cancer Lett. 2024 Nov 25:217356. doi: 10.1016/j.canlet.2024.217356.
    >> Share

  97. GERRATANA L, Davis AA, Foffano L, Reduzzi C, et al
    Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling.
    Cancer Lett. 2024 Nov 20:217325. doi: 10.1016/j.canlet.2024.217325.
    >> Share

  98. TRAPPETTI V, Fernandez-Palomo C, Arora P, Potez M, et al
    "Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams".
    Cancer Lett. 2024 Nov 13:217326. doi: 10.1016/j.canlet.2024.217326.
    >> Share

  99. LIU K, Hoover AR, Wang L, Sun Y, et al
    Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.
    Cancer Lett. 2024;604:217267.
    >> Share

    October 2024
  100. BHATTARAI PY, Kim G, Lim SC, Choi HS, et al
    METTL3-STAT5B interaction facilitates the co-transcriptional m(6)A modification of mRNA to promote breast tumorigenesis.
    Cancer Lett. 2024;603:217215.
    >> Share

    September 2024
  101. YU L, Wei W, Lv J, Lu Y, et al
    FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity.
    Cancer Lett. 2024 Sep 19:217271. doi: 10.1016/j.canlet.2024.217271.
    >> Share

  102. WINNARD PT JR, Vesuna F, Bol GM, Gabrielson KL, et al
    Targeting RNA Helicase DDX3X with a Small Molecule Inhibitor for Breast Cancer Bone Metastasis Treatment.
    Cancer Lett. 2024 Sep 19:217260. doi: 10.1016/j.canlet.2024.217260.
    >> Share

  103. LIU X, Ma Z, Jing X, Wang G, et al
    The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer.
    Cancer Lett. 2024 Sep 12:217232. doi: 10.1016/j.canlet.2024.217232.
    >> Share

  104. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Cancer Lett. 2024 Sep 5:217219. doi: 10.1016/j.canlet.2024.217219.
    >> Share

  105. ZHANG Z, Zhao M, Wang Q, Wang X, et al
    Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance.
    Cancer Lett. 2024;599:217147.
    >> Share

    August 2024
  106. GAO Q, Li N, Pan Y, Chu P, et al
    Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulation.
    Cancer Lett. 2024 Aug 31:217196. doi: 10.1016/j.canlet.2024.217196.
    >> Share

  107. SRIVASTAVA P, Jha S, Singh SK, Vyas H, et al
    Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis.
    Cancer Lett. 2024;603:217200.
    >> Share

  108. MA Y, Zhang H, Shen X, Yang X, et al
    Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
    Cancer Lett. 2024;598:217102.
    >> Share

  109. LIU B, Liu Y, Yang S, Ye J, et al
    Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER(+) breast cancer.
    Cancer Lett. 2024;600:217179.
    >> Share

  110. GU T, Vasilatos SN, Yin J, Qin Y, et al
    Restoration of TFPI2 by LSD1 Inhibition Suppresses Tumor Progression and Potentiates Antitumor Immunity in Breast Cancer.
    Cancer Lett. 2024 Aug 16:217182. doi: 10.1016/j.canlet.2024.217182.
    >> Share

  111. VIDANA GAMAGE HE, Albright ST, Smith AJ, Farmer R, et al
    Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.
    Cancer Lett. 2024;597:217086.
    >> Share

  112. VIDANA GAMAGE HE, Shahoei SH, Wang Y, Jacquin E, et al
    NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.
    Cancer Lett. 2024;597:217042.
    >> Share

  113. REGUA AT, Bindal S, Najjar MK, Zhuang C, et al
    Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Cancer Lett. 2024;597:217023.
    >> Share

  114. YANG Y, Hao X, Zhang J, Gao T, et al
    The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling.
    Cancer Lett. 2024 Aug 8:217157. doi: 10.1016/j.canlet.2024.217157.
    >> Share

  115. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    >> Share

  116. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    >> Share

    July 2024
  117. LI M, Zhang L, Guan T, Huang L, et al
    Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
    Cancer Lett. 2024;595:216987.
    >> Share

  118. LIU Y, Yin S, Lu G, Du Y, et al
    The intersection of the nervous system and breast cancer.
    Cancer Lett. 2024;598:217132.
    >> Share

  119. LIU M, Zhao Z, Wang C, Sang S, et al
    Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
    Cancer Lett. 2024;594:216991.
    >> Share

  120. ZHANG H, Zhang L, He Y, Jiang D, et al
    PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
    Cancer Lett. 2024 Jul 8:217112. doi: 10.1016/j.canlet.2024.217112.
    >> Share

  121. FU Z, Zhang L, Chen R, Zhan J, et al
    Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
    Cancer Lett. 2024;598:217099.
    >> Share

    June 2024
  122. LIAO Q, Shi H, Yang J, Ge S, et al
    FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors.
    Cancer Lett. 2024;592:216911.
    >> Share

  123. WAN YX, Qi XW, Lian YY, Liu ZY, et al
    Electroacupuncture Facilitates Vascular Normalization by Inhibiting Glyoxalase1 in Endothelial Cells to Attenuate Glycolysis and Angiogenesis in Triple-Negative Breast Cancer.
    Cancer Lett. 2024 Jun 28:217094. doi: 10.1016/j.canlet.2024.217094.
    >> Share

  124. YU Y, Cao WM, Cheng F, Shi Z, et al
    FOXK2 amplification promotes breast cancer development and chemoresistance.
    Cancer Lett. 2024 Jun 18:217074. doi: 10.1016/j.canlet.2024.217074.
    >> Share

  125. LIU J, Zhai M, Chen Y, Wei Y, et al
    Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression.
    Cancer Lett. 2024 Jun 14:217005. doi: 10.1016/j.canlet.2024.217005.
    >> Share

  126. WANG S, Xu L, Wang D, Zhao S, et al
    YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.
    Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047.
    >> Share

  127. LI SY, Zhang N, Zhang H, Wang N, et al
    Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
    Cancer Lett. 2024;597:216995.
    >> Share

  128. ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al
    Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A.
    Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008.
    >> Share

  129. OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al
    Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011.
    >> Share

  130. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    >> Share

    May 2024
  131. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    >> Share

  132. LV Y, Sun S, Zhang J, Wang C, et al
    Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
    Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
    >> Share

  133. WANG J, Hirose H, Du G, Chong K, et al
    Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
    Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966.
    >> Share

  134. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    >> Share

  135. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    >> Share

    April 2024
  136. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    >> Share

  137. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    >> Share

  138. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    >> Share

  139. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    >> Share

  140. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    >> Share

  141. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    >> Share

  142. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    >> Share

    March 2024
  143. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    >> Share

  144. IDRISS MH, Stull CM, Migden MR
    Treatments on the horizon for locally advanced basal cell carcinoma.
    Cancer Lett. 2024;589:216821.
    >> Share

  145. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    >> Share

  146. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    >> Share

    February 2024
  147. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    >> Share

  148. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    >> Share

  149. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    >> Share

  150. MURTHY D, Dutta D, Attri KS, Samanta T, et al
    CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven fatty acid beta-oxidation in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724.
    >> Share

  151. XIONG H, Zhai Y, Meng Y, Wu Z, et al
    Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
    Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732.
    >> Share

  152. BAHREYNI A, Mohamud Y, Luo H
    Oncolytic virus-based combination therapy in breast cancer.
    Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634.
    >> Share

  153. TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al
    Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3beta/beta-catenin/EMT pathway.
    Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653.
    >> Share

    January 2024
  154. CHEN SY, Zhang FL, Zhang YL, Liao L, et al
    Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression.
    Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672.
    >> Share

  155. LIU C, Qian X, Yu C, Xia X, et al
    Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling axis in triple-negative breast cancer.
    Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642.
    >> Share

  156. JIA F, Sun S, Li J, Wang W, et al
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016